A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
← catalyst calendarSponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
1
Country
Austria
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-06 | actual | When the study began enrolling |
| Primary completion | Oct 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Intervention
- Drug: Tildrakizumab — also filed as Ilumetri®
Primary outcomes
what the primary-completion date above is the date OFTreatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score
measured Baseline, Week 28
World Health Organisation Well-Being Index (WHO-5) Score
measured Baseline up to Week 28
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed